| pubmed-article:12419750 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12419750 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:12419750 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:12419750 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:12419750 | lifeskim:mentions | umls-concept:C2239176 | lld:lifeskim |
| pubmed-article:12419750 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:12419750 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:12419750 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:12419750 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:12419750 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:12419750 | pubmed:dateCreated | 2002-11-6 | lld:pubmed |
| pubmed-article:12419750 | pubmed:abstractText | We determined the maximum tolerated dose (MTD) and then further evaluated the response rate and safety profile of gemcitabine (Gem) plus doxorubicin (Dox) in chemonaïve patients with advanced hepatocellular carcinoma (HCC). | lld:pubmed |
| pubmed-article:12419750 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12419750 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12419750 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12419750 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12419750 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12419750 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12419750 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12419750 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:12419750 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:12419750 | pubmed:author | pubmed-author:WangC HCH | lld:pubmed |
| pubmed-article:12419750 | pubmed:author | pubmed-author:ChenJ SJS | lld:pubmed |
| pubmed-article:12419750 | pubmed:author | pubmed-author:YangT STS | lld:pubmed |
| pubmed-article:12419750 | pubmed:author | pubmed-author:HsiehR KRK | lld:pubmed |
| pubmed-article:12419750 | pubmed:author | pubmed-author:FungM CMC | lld:pubmed |
| pubmed-article:12419750 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12419750 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:12419750 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12419750 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12419750 | pubmed:pagination | 1771-8 | lld:pubmed |
| pubmed-article:12419750 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:meshHeading | pubmed-meshheading:12419750... | lld:pubmed |
| pubmed-article:12419750 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12419750 | pubmed:articleTitle | Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial. | lld:pubmed |
| pubmed-article:12419750 | pubmed:affiliation | Department of Internal Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan. | lld:pubmed |
| pubmed-article:12419750 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12419750 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12419750 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:12419750 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:12419750 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:12419750 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:12419750 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12419750 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12419750 | lld:pubmed |
